Meera Tugnait

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Scott Gettinger, Lyudmila Bazhenova, Corey J. Langer et al. · The Lancet Oncology · 2016 · 348 citations

Other Malignancies, Medicine, Pharmacology +7

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Michael C. Heinrich, Robin L. Jones, Margaret von Mehren et al. · The Lancet Oncology · 2020 · 294 citations

Tumor Biology, Gastrointestinal Oncology, Medicine +5

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer et al. · Cancer Discovery · 2019 · 239 citations · Full text

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

Daniel J. DeAngelo, Deepti Radia, Tracy I. George et al. · Nature Medicine · 2021 · 139 citations · Full text

Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors

Vincent Mascitti, Tristan S. Maurer, Ralph P. Robinson et al. · Journal of Medicinal Chemistry · 2011 · 133 citations · Full text

Pharmaceutical Science, Clinical Candidate, Pharmacotherapy +16